Prostate cancer classified as Gleason score 2 (G2) is generally considered a low-to-intermediate risk group and, in appropriately selected patients, can be successfully treated with surgical intervention. At this stage, the biological behavior of the disease plays an important role in treatment planning.
In G2 prostate cancer, the treatment approach is determined by considering the patient’s age, overall health status, local extent of the tumor, and patient expectations. Laparoscopic surgery may be evaluated as a minimally invasive option in selected patients.
Diagnostic and Evaluation Process
The diagnosis of G2 prostate cancer is based on a combined assessment of PSA levels, prostate biopsy results, clinical examination, and imaging studies. The tumor’s status within the prostate capsule and its relationship with surrounding tissues are analyzed in detail to accurately determine the stage of the disease.
This evaluation guides the decision regarding the suitability and extent of surgical treatment.
Laparoscopic Surgical Approach
In G2 prostate cancer, laparoscopic surgery is a minimally invasive technique aimed at complete removal of the prostate gland. Performed through small incisions using a camera and specialized surgical instruments, this approach allows for increased surgical precision.
Laparoscopic surgery may offer advantages such as reduced bleeding, a faster recovery period, and a shorter hospital stay. With appropriate patient selection, safe and effective outcomes are targeted.
Post-Treatment Follow-Up
After surgery, patients are enrolled in a regular follow-up program. Disease progression is monitored through PSA testing, clinical evaluations, and imaging studies when necessary.
The goals of the treatment process are effective cancer control, preservation of functional outcomes, and maintenance of the patient’s quality of life at the highest possible level.
